Project Details
Description
Project Summary
The goal of our R21 project is to develop a powerful platform that will be able to generate and assay
millions of combinations of CRISPR/Cas9 single-guide RNAs (sgRNAs) or other genetic perturbagens. Doing
so will clear the way for systematic exploration of genetic interactions in mammalian cells. There are many
reasons to develop this high-throughput mammalian genetic technology. Currently there is no systematic
method to unravel the assortment of genetic interactions that drive specific cancers and determine the
variability of individual treatment responses. Nor is there a robust method to study gene interactions in other
complex multigenic diseases such as Parkinson's.
We are motivated by the tremendous advances recently made in yeast and worms that have resulted from
systematic discovery of genetic interactions. Genetic interaction maps in yeast have revealed functional
relationships within and between protein complexes orders of magnitude beyond those revealed by protein-
protein interaction screens. Systematic screening 65,000 pairs of genes in worms led to the identification of a
class of highly connected `hub' genes encoding chromatin regulators. The technologies behind these
discoveries depend on several high-throughput steps, including a dependable gene knockout or knockdown
method, a method to deliver two gene knockouts/knockdowns into the same cell and to monitor which cells
receive which combinations, and also a reliable assay to measure relative fitness.
Our major enabling technology for development of a high-throughput system for mammalian cells is the
tandem-integration landing pad that allows two plasmids to be inserted next to each other at a neutral location
of the genome. Each plasmid contains a DNA barcode that uniquely identifies the associated genetic
perturbagen (e.g. sgRNAs). When both plasmids are integrated into the genome, the two barcodes are in close
enough proximity to be sequenced together by paired-end amplicon sequencing. We have established this
methodology in yeast and have shown that it can generate a library of >108 double barcoded cells via pooled
sequential plasmid transformation and integration. The fitness of large double barcode libraries can then be
measured using the fit-seq approach that we pioneered: pooled growth and double barcode amplicon
sequencing over several time points accurately measures the relative fitness of each double barcoded cell in
the pool. In yeast, Genetic interaction Sequencing (GiSeq) promises to be a cheaper and higher-throughput
alternative to the commonly used synthetic-genetic array technology. In mammalian cells, GiSeq promises to
be a major leap forward over existing technologies: not only will genome-scale interaction libraries become
practical, but negligible work will be needed to repeat a screen in a different cells or different conditions.
For this proposal, we will establish the utility of GiSeq in mammalian cells (Aims 1 and 2), and prepare
reagents to perform genetic interaction screens in vivo (Aim 3).
| Status | Finished |
|---|---|
| Effective start/end date | 09/28/16 → 06/30/18 |
Funding
- National Human Genome Research Institute: $399,479.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.